SLDB Solid Biosciences Forecast, Technical & Fundamental Analysis
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases... Show more
SLDB is expected to report earnings to fall 20.60% to -41 cents per share on November 11
Q3'26
Est.
$-0.41
Q1'26
Beat
by $0.13
Q4'25
Beat
by $0.09
Q3'25
Beat
by $0.17
Q2'25
Beat
by $0.22
The last earnings report on May 12 showed earnings per share of -51 cents, beating the estimate of -64 cents. With 243.12K shares outstanding, the current market capitalization sits at 1.10B.
A.I. Advisor
published General Information
General Information
a developer of novel gene therapy platform for advancing disease
A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.
SLDB in -1.30% downward trend, declining for three consecutive days on August 18, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLDB declined for three days, in of 365 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SLDB moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
SLDB broke above its upper Bollinger Band on August 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on SLDB as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on August 07, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
SLDB moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SLDB crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 157 cases where SLDB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.938) is normal, around the industry mean (20.572). P/E Ratio (0.000) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.169).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
